Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications

IF 3.8 3区生物学 Q1 BIOCHEMICAL RESEARCH METHODS

Expert Review of Proteomics Pub Date : 2022-02-01 DOI:10.1080/14789450.2022.2070477

L. Dayon, O. Cominetti, M. Affolter

{"title":"Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications","authors":"L. Dayon, O. Cominetti, M. Affolter","doi":"10.1080/14789450.2022.2070477","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Biological fluids are routine samples for diagnostic testing and monitoring. Blood samples are typically measured because of their moderate invasive collection and high information content on health and disease. Several body fluids, such as cerebrospinal fluid (CSF), are also studied and suited to specific pathologies. Over the last two decades, proteomics has quested to identify protein biomarkers but with limited success. Recent technologies and refined pipelines have accelerated the profiling of human biological fluids. Areas covered We review proteomic technologies for the identification of biomarkers. These are based on antibodies/aptamers arrays or mass spectrometry (MS), but new ones are emerging. Advances in scalability and throughput have allowed to better design studies and cope with the limited sample size that has until now prevailed due to technological constraints. With these enablers, plasma/serum, CSF, saliva, tears, urine, and milk proteomes have been further profiled; we provide a non-exhaustive picture of some recent highlights (mainly covering literature from the last 5 years in the Scopus database) using MS-based proteomics. Expert opinion While proteomics has been in the shadow of genomics for years, proteomic tools and methodologies have reached certain maturity. They are now better suited to discover innovative and robust biofluid biomarkers.","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"9 1","pages":"131 - 151"},"PeriodicalIF":3.8000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Proteomics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/14789450.2022.2070477","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 20

Abstract

ABSTRACT Introduction Biological fluids are routine samples for diagnostic testing and monitoring. Blood samples are typically measured because of their moderate invasive collection and high information content on health and disease. Several body fluids, such as cerebrospinal fluid (CSF), are also studied and suited to specific pathologies. Over the last two decades, proteomics has quested to identify protein biomarkers but with limited success. Recent technologies and refined pipelines have accelerated the profiling of human biological fluids. Areas covered We review proteomic technologies for the identification of biomarkers. These are based on antibodies/aptamers arrays or mass spectrometry (MS), but new ones are emerging. Advances in scalability and throughput have allowed to better design studies and cope with the limited sample size that has until now prevailed due to technological constraints. With these enablers, plasma/serum, CSF, saliva, tears, urine, and milk proteomes have been further profiled; we provide a non-exhaustive picture of some recent highlights (mainly covering literature from the last 5 years in the Scopus database) using MS-based proteomics. Expert opinion While proteomics has been in the shadow of genomics for years, proteomic tools and methodologies have reached certain maturity. They are now better suited to discover innovative and robust biofluid biomarkers.

查看原文本刊更多论文

人类生物流体蛋白质组学的生物标志物发现:技术进步和最新应用

生物体液是诊断检测和监测的常规样本。血液样本是典型的测量，因为它们的中度侵入性收集和高信息含量的健康和疾病。一些体液，如脑脊液(CSF)，也被研究并适合于特定的病理。在过去的二十年里，蛋白质组学一直试图识别蛋白质生物标志物，但收效甚微。最近的技术和精炼的管道加速了人体生物流体的分析。我们回顾了用于生物标志物鉴定的蛋白质组学技术。这些方法是基于抗体/适体阵列或质谱(MS)，但新的方法正在出现。在可扩展性和吞吐量方面的进步使得更好地设计研究和应对有限的样本量，这种样本量由于技术限制而一直存在。有了这些使能剂，血浆/血清、脑脊液、唾液、眼泪、尿液和牛奶蛋白质组被进一步分析;我们使用MS-based蛋白质组学提供了一些最近的亮点(主要包括Scopus数据库中最近5年的文献)的非详尽的图片。虽然多年来蛋白质组学一直处于基因组学的阴影下，但蛋白质组学的工具和方法已经达到了一定的成熟度。它们现在更适合于发现创新和强大的生物流体生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Proteomics 生物-生化研究方法

CiteScore

7.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Proteomics (ISSN 1478-9450) seeks to collect together technologies, methods and discoveries from the field of proteomics to advance scientific understanding of the many varied roles protein expression plays in human health and disease. The journal coverage includes, but is not limited to, overviews of specific technological advances in the development of protein arrays, interaction maps, data archives and biological assays, performance of new technologies and prospects for future drug discovery. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion - a personal view on the most effective or promising strategies and a clear perspective of future prospects within a realistic timescale Article highlights - an executive summary cutting to the author''s most critical points.